Arca
Skip to content
Tools
Tools

Label Changes: Ogsiveo (nirogacestat hydrobromide)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Ogsiveo label DailyMed has published, from Springworks Therapeutics, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 10
  • Sections changed, version 15 to 16: 5

What changed from version 15 to version 16

Aug 10, 2026 to Sep 2, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Dosage and administrationChanged · 18 words added
  2. Warnings and precautionsChanged · 52 words added, 1 removed
  3. Adverse reactionsChanged · 8 words added
  4. Patient counseling informationChanged · 40 words added, 1 removed
  5. Patient informationChanged · 139 words added, 32 removed

Dosage and administration

Changed18 words added
13 unchanged lines
Hypokalemia despite maximal replacement therapy [see Warnings and Precautions ( 5.5 ) ] | Grades 3 or 4 | Withhold OGSIVEO until resolved to Grade ≤ 1 or baseline, then restart at a dosage of 100 mg twice daily.
Anaphylaxis or other severe hypersensitivity reaction [see Warnings and Precautions (5.6)] | Grades 3 or 4 | Permanently discontinue.

Warnings and precautions

Changed52 words added, 1 removed
11 unchanged lines
Electrolyte abnormalities can occur in patients treated with OGSIVEO. In DeFi, these included decreased phosphate (65%) and decreased potassium (22%). Phosphate <2 mg/dL occurred in 20% of patients who received OGSIVEO. Grade 3 decreased potassium occurred in 1.4% of patients [ see A dverse Reactions ( 6.1 ) ]. Monitor phosphate and potassium levels regularly and supplement as necessary. Modify dose as recommended [see Dosage and Administration ( 2.2 ) ].
5.6 Hypersensitivity Reactions
Hypersensitivity reactions, including severe hypersensitivity reactions, have been reported with postmarketing use of OGSIVEO. Monitor patients for signs and symptoms of hypersensitivity during treatment with OGSIVEO and manage as clinically indicated. Interrupt dosing or permanently discontinue OGSIVEO depending on the severity [see Dosage and Administration (2.2)].
5. 67 Embryo-Fetal Toxicity
Based on findings from animal studies and its mechanism of action, OGSIVEO can cause fetal harm when administered to pregnant women. Oral administration of nirogacestat to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity and death at maternal exposures below the human exposure at the recommended dose of 150 mg twice daily. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose [ see Use in Specific Populations ( 8.1 , 8.3 ) ].

Adverse reactions

Changed8 words added
6 unchanged lines
Electrolyte Abnormalities [ see Warnings and Precautions ( 5.5 )]
Hypersensitivity Reactions [see Warnings and Precautions (5.6)]
6.1 Clinical Trials Experience
50 unchanged lines

Patient counseling information

Changed40 words added, 1 removed
11 unchanged lines
Advise patients that OGSIVEO can cause hypophosphatemia and/or hypokalemia which may require phosphate and/or potassium supplementation. Advise patients that they will be monitored for these and to contact their healthcare provider if they experience muscle pain or weakness [ see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.5 ) ].
Hypersensitivity
Advise patients that hypersensitivity reactions, including potentially severe reactions, may occur during treatment with OGSIVEO and to immediately report any signs and symptoms to their healthcare provider [see Dosage and Administration (2.2) , Warnings and Precautions (5.6)].
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential harm to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy, and to stop taking OGSIVEO if they become pregnant. Advise females of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose. Addition of a barrier method is recommended for females using hormonal contraceptives. Advise males with female partners of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose [see Warnings and Precautions ( 5.67 ) , Use in Specific Populations ( 8.3 ) ].
Lactation
7 unchanged lines

Patient information

Changed139 words added, 32 removed
4 unchanged lines
What should I avoid while taking OGSIVEO? Avoid eating or drinking grapefruit products, Seville oranges, and starfruit during treatment with OGSIVEO.
What are the possible side effects of OGSIVEO? OGSIVEO can cause serious side effects, including: Diarrhea. Diarrhea is common during treatment with OGSIVEO and may sometimes be severe. Your healthcare provider may tell you to drink more fluids or may tell you to take antidiarrheal medicines. Tell your healthcare provider right away if you have diarrhea that lasts longer than a few days and does not get better after taking antidiarrheal medicines. Ovarian problems. Females who are able to become pregnant may have ovarian problems and changes in their menstrual cycle during treatment with OGSIVEO. OGSIVEO may affect fertility which may affect your ability to have a child. Tell your healthcare provider if you have any changes in your menstrual cycle or any hot flashes, night sweats or vaginal dryness during treatment with OGSIVEO. Liver problems. OGSIVEO can cause an increase in liver enzymes. Your healthcare provider will do blood tests to check your liver function before you start and during your treatment with OGSIVEO. New non-m elanoma s kin c ancers. Your healthcare provider will do skin exams before and during treatment with OGSIVEO if you are at risk for skin cancer. Tell your healthcare provider if you have any new or changing skin lesions. Electrolyte (salt) problems. Your healthcare provider will do blood tests to check your phosphate and potassium levels during treatment with OGSIVEO and may give you medicines to treat low phosphate or low potassium if needed. Tell your healthcare provider if you develop any muscle pain or weakness. TheSerious mostallergic commonreactions. sideOGSIVEO effectscan cause allergic reactions that can be severe. Tell your healthcare provider right away if you develop any signs or symptoms of OGSIVEOa includesevere allergic reaction during treatment with OGSIVEO, including:
diarrhea | headache
ovarian problems | stomach (abdominal) pain
rash | cough
nausea | hair loss
tiredness | upper respiratory infection
mouth sores | shortness of breath
| skin rash itching hives chest pain fast heart rate | wheezing or trouble breathing swelling of the face, eyes, lips, tongue or throat dizziness or lightheadedness fever muscle or joint pain
| Your healthcare provider will monitor you for signs or symptoms of a severe allergic reaction during treatment with OGSIVEO and may temporarily or completely stop treatment with OGSIVEO if you develop any signs or symptoms of a severe allergic reaction.
The most common side effects of OGSIVEO include:
| diarrhea ovarian problems rash nausea tiredness mouth sores | headache stomach (abdominal) pain cough hair loss upper respiratory infection shortness of breath
The most common abnormal lab tests results with OGSIVEO include: decreased phosphate, increased sugar (glucose) and protein in the urine, increased liver enzymes, and decreased potassium. OGSIVEO may affect fertility in females and males, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of OGSIVEO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How do I store OGSIVEO? Store OGSIVEO tablets at room temperature between 68°F to 77°F (20°C to 25°C). Keep OGSIVEO and all medicines out of the reach of children.
General information about safe and effective use of OGSIVEO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use OGSIVEO for a condition for which it is not prescribed. Do not give OGSIVEO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare providerpharmacist or pharmacisthealthcare provider for information about OGSIVEO that is written for health professionals.
What are the ingredients in OGSIVEO? Active ingredient: nirogacestat Inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate type A. Film Coating ingredients: FD&C yellow #6/sunset yellow FCF aluminum lake, glycerol monocaprylocaprate type 1/mono/diglycerides, iron oxide yellow, macrogol (PEG) polyvinyl alcohol graft copolymer, polyvinyl alcohol – partially hydrolyzed, talc, and titanium dioxide. Manufactured for SpringWorks Therapeutics, Inc. Stamford, CT 06902. OGSIVEO® is a trademark of SpringWorks Therapeutics Operating Company, Inc. ©2026 SpringWorks Therapeutics, Inc.
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 0308/2026

Unchanged: Indications and usage, Dosage forms and strengths, Contraindications, Drug interactions, Use in specific populations, Overdosage, Description, Clinical pharmacology, Nonclinical toxicology, Clinical studies, How supplied, Principal display panel.

Every version

10 versions of set f172e6ff-3190-41b0-b95a-58a7ef9e9e1e, newest first.
VersionPublished on DailyMedCompareSPL file
16Sep 2, 2026Shown belowDownload .zip
15Aug 10, 2026With version 14Download .zip
14Mar 26, 2026With version 11Download .zip
11Nov 17, 2025With version 9Download .zip
9Nov 25, 2024With version 8Download .zip
8May 9, 2024With version 7Download .zip
7May 2, 2024With version 6Download .zip
6Dec 19, 2023With version 5Download .zip
5Dec 7, 2023With version 4Download .zip
4Dec 5, 2023First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.